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with bicuspid aortic valves excluded from
the study? Did patients with Gothic arches
and bicuspid valves have even greater
changes? Did any of the patients with
Gothic arch and a tricuspid aortic valve
have aortic insufficiency or require valve
replacement/repair?
Approximately 15% of patients who are
status-post repair of type I aortic dissection
require replacement of the proximal de-
scending aortic owing to increasing diame-
ter on long-term follow-up. It has also
been my impression that those patients
who have repair of type I aortic dissection
with replacement of the ascending aorta
and hemiarch repair have a greater incidence
of progressive aortic insufficiency and may
require aortic valve replacement or aortic
root replacement. This cohort is in contrast
to those patients with type I aortic dissection
who simply had ascending aortic replace-
ment and appeared to have a lesser inci-
dence of aortic insufficiency and valve or
root replacement over the long term.
Might the hemodynamic changes that
were documented in the pediatric angular
Gothic arch be present in this status-post
aortic dissection group and predispose to
aortic valve insufficiency and dilation of
the proximal portion of the distal descend-
ing thoracic aorta? Might this effect be
more pronounced in the hemiarch repair
that predisposes to an angular Gothic arch
configuration? Replacement of the ascend-
ing aorta only (without hemiarch repair)
usually preserves the concave configura-
tion of the ascending aorta and its gentle
curve into the transverse arch. Ascending
aorta and hemiarch replacement typically
has an angulated Gothic configuration
rather than the gentle curve that nature
favors.
Frank A. Baciewicz, Jr, MD
Professor of Cardiothoracic Surgery
Wayne State University
School of Medicine
Detroit, MI 48201
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Aprotinin and renal dysfunction:
The role of exposure to
angiotensin-converting enzyme
inhibitors
To the Editor:
I read with great interest the recent article by
Pagano and colleagues1 detailing their fa-
vorable experience with aprotinin in a large
patient series (N 5 7836: 1998–2006) from
a single institution. The authors demon-
strated that aprotinin exposure did not
significantly affect the incidence of postop-
erative renal dysfunction.
Careful review of this interesting paper re-
veals, however, that although hypertension
was significantly more common in the aproti-
nin cohort (63.3% vs 55.1%; P , .001), the
incidenceof exposure to angiotensin-convert-
ing enzyme (ACE) inhibitors is not indicated.
This is an important confounder, inasmuch as
ACE inhibitors in conjunction with aprotinin
have been shown to be associated with renal
dysfunction after cardiac surgery.2,3
As a consequence of this observation, I
have the following questions:
1. What was the incidence of ACE
inhibitor therapy in the aprotinin
cohort?
2. Was exposure to ACE inhibitors sig-
nificantly different in the aprotinin
cohort?
3. What was the percentage of off-pump
coronary bypass procedures, given
that aprotinin and ACE inhibitors
have recently been significantly asso-
ciated with postoperative renal dys-
function in this patient subgroup?3
4. Could the incidence ofACE inhibitor
exposure have confounded the re-
sults of the study, given the findings
from the literature?2,3 For example,
could a lack of renal toxicity from
aprotinin be explained by a low inci-
dence of exposure to ACE inhibitors
in the aprotinin cohort?
I congratulate the authors again on their
important contribution. I look forward to
their feedback about the impact of ACE
exposure and aprotinin on renal dysfunction
after cardiac surgery.
John G. T. Augoustides, MD, FASE
Associate Professor
Department of Anesthesiology and Critical Care
Hospital of the University of Pennsylvania
Philadelphia, PA 19104-4283
Financial support: Department of Anesthesiology
and Critical Care, Hospital of the University of
Pennsylvania.
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Reply to the Editor:
Dr Augoustides raises an appropriate point.
It is the policy in our unit to discontinue
angiotensin-converting enzyme inhibitors
or equivalents 24 hours before the operation
and for patients with impaired renal func-
tion, at least 48 hours before the operation.
However our database does not have infor-
mation on compliance to this policy. There-
fore, we could not address this issue in our
article.1
Domenico Pagano, MD, FRCS, FESC
Department of Cardiothoracic Surgery
University Hospital Birmingham
Edgbaston
Birmingham, West Midlands, United Kingdom
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Letters to the EditorProsthetic valve thrombosis: A
regimen of treatment with low-
dose and longer-course using
recombinant tissue-type
plasminogen activator is
a promising protocol
To the Editor:
Despite the progress in anesthesia, cardiac
surgery, and perioperative care, the thera-
peutic decision in prosthetic valve thrombo-
sis (PVT) remains in discussion.
In recent years thrombolytic therapy has
won acceptance, and for many it is the first
Optimizing selective cerebral
perfusion in adult aortic arch
repair: Clinical relevance of the
laboratory model
To the Editor:
I read with great interest the excellent article
by Halstead and colleagues1 detailing in
their porcine model of deep hypothermic
circulatory arrest (DHCA) the neuroprotec-
tive effects of selective cerebral perfusion
(SCP) via both carotid arteries at a mean
of 50 mm Hg for a period of 90 minutes.
In this laboratory model, the authors have
clearly demonstrated the adverse cerebral
effects associated with SCP at higher pres-
sures and flow rates. The clinical relevance
of this observation is illustrated in the study
by Khaladji and colleagues,2 in which they
analyze outcomes after hypothermic circu-
latory arrest (71.1% hemiarch; 10.4% total
arch) and bilateral cold selective SCP at
a perfusion pressure of 40 to 60 mm Hg
with flow rates of 400 to 650 mL/min.
However, Halstead and colleagues chose
a long SCP time of 90 minutes, which is the
time required for a total arch repair. In an ear-
lier clinical study, these investigators3 dem-
onstrated their technique with a trifurcated
graft with mean DHCA/SCP times of 31.1
6 6.6 minutes and 65.36 20.9 minutes, re-
spectively, with SCP perfusion pressures of
50 to 70 mm Hg with flow rates of 800 to
1200 mL/min. Hence, this latest laboratory
study is part of their ongoing quest to opti-
mize their technique of total arch replace-
ment with SCP, and it suggests a new
range for bilateral SCP perfusion pressures
and flow rate.
However, although this model is clini-
cally relevant for hemiarch repairs,2 how
might it apply in the case of aortic arch repair
with unilateral SCP?4Would lower SCP per-
fusion pressures be clinically superior, as-
suming a clinically competent circle of
Willis? Or would the contralateral brain be
at significant risk of ischemia, given the rel-
evant incidence of clinical inadequacy in the
circle of Willis for cerebral perfusion in
DHCAwith unilateral SCP?5 Do the authors
plan to evaluate unilateral SCP in their por-
cine DHCA model?
I congratulate the authors again on their
important contribution. I look forward to their
comments about these aspects of selective ce-
rebral perfusionduring adult aortic arch repair.
John G. T. Augoustides, MD, FASE
Associate Professor
Department of Anesthesiology and Critical Care
Hospital of the University of Pennsylvania
Philadelphia, PA 19104-4283
Financial support: Department of Anesthesiology
and Critical Care, Hospital of the University of
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Letters to the Editortherapeutic choice because the mortality is
lower than that of surgical treatment and
its application is easy and rapid.1,2
We do not know with certainty how long
it takes thrombolytic therapy to deocclude
a thrombosed prosthesis, although it proba-
bly takes less time than surgery because of
all the equipment needed to implement
aggressive treatment.
The great risk of a redo valve replace-
ment in these generally critically ill patients
is also widely appreciated. The main risks of
thrombolytic treatment are the thromboem-
bolic complications, which appear in from
4% to 13% of the patients, and bleeding,
which occurs in from 1.4% to 5%.3
We have read with interest the excellent
report written by Nguyen and collegues.4
They have added an important case to the
medical literature for the successful applica-
tion of the thrombolytic protocol with
recombinant tissue-type plasminogen acti-
vator (rt-PA), which has not been used
previously in the management of PVT. It
consisted in a continuous intravenous infu-
sion of rt-PA at a rate of 1 mg/h together
with the administration of heparin in a con-
tinuous intravenous infusion of 3 U $ kg21 $
h21. The duration of treatment was 80
hours. At the end of the fibrinolytic infusion,
the transprosthetic gradients had decreased
from a peak and mean of 158 and 86 mm
Hg to 48 and 25 mm Hg, respectively. Fluo-
roscopy confirmed normal motion of the
prosthetic valve. The patient’s symptoms re-
solved.
We would like to make some comments
related to this therapeutic regimen. Treat-
ment with rt-PA in PVT has not been widely
used. It has been blamed for a major risk of
embolism other than thrombolysis for its po-
tential and velocity of the infusion. Shapira
and collegues5 proved the efficacy and
safety of rt-PA, with the additional advan-
tage that if the thrombolytic treatment fails,
surgery can be used with less risk for its less
lytic systemic effect.
The regimen of administration is not
well defined. This protocol probably needs
a longer course and lower dose to provide
better thrombolytic efficacy with less risk
of complications in hemodynamically stable
patients, because they do not need a prompt
thrombolytic effect. An accelerated protocol
with rt-PA should be reserved for critically
ill patients.
Until now, streptokinase is the most ef-
fective thrombolytic agent used, alone oras a part of a sequential fibrinolytic treat-
ment in the PVT.
Despite the favorable evidence of throm-
bolytic therapy in the treatment of the PVT,
more data should be gathered to obtain
a general consensus of the ideal manage-
ment of this complication.
Fidel Manuel Ca´ceres-Lo´riga, MD, PhD
Horacio Pe´rez-Lo´pez, MD, PhD
Karel Morlans-Herna´ndez, MD
Institute of Cardiology and
Cardiovascular Surgery
Havana, Cuba
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